Teva Fails On Quillivant XR Appeal – Five Years After Winning
Remanded 2020 District Court Decision Affirmed On Appeal
Executive Summary
Teva’s Actavis looks unlikely to be launching its proposed generic version of Tris Pharma’s Quillivant XR (methylphenidate) extended-release oral suspension soon, after a remanded district court decision that went against the firm was upheld on appeal.
You may also be interested in...
Teva Fails To Sidestep Eight Of Nine QuilliChew ER Patent Claims
A proposed Teva Pharmaceutical generic would infringe on multiple patents for Tris Pharma’s QuilliChew ER, a New Jersey district court has ruled.
Teva Falls Short On Challenge To Velphoro Formulation Patent
Teva has been shot down in its attempts to circumvent a key US patent shielding Vifor Pharma’s Velphoro dialysis drug.
Actavis Quillivant XR finding is overturned
Actavis has suffered a setback in its attempts to bring a generic of Tris Pharma’s Quillivant XR (methylphenidate) extended-release suspension to market ahead of patent expiry, after a US Court of Appeals vacated and remanded a favourable district court ruling on numerous patent claims due to “inadequate fact-findings”.